Logo


Glenmark eyes big growth in US with cholesterol drug launch

The drug maker earns about 35% of its revenue from the US market

Glenmark eyes big growth in US with cholesterol drug launch

Drugmaker Glenmark’s US business has received a boost with the launch of the first generic version of cholesterol drug Zetia in the market. Glenmark has 180 days exclusivity for the sale of generic version of the drug, which has a market size of $2.6 billion, and the company aims to use the sale proceeds to reduce debt. The product was launched on Monday.  The drugmaker earns 35 per cent of its revenue from the US market. Overall, generic drugmakers are facing an impact of channel consolidation and price erosion in the US market. Indian companies have ...